This work furthers our understanding of therapeutic resistance in CRC and offers a rationale for targeting BCL-3 as an adjuvant to conventional therapies, particularly in the setting of neo-adjuvant therapy for locally advanced rectal cancer. The gene discussed is BCL3; the disease is colorectal carcinoma.